8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________

FORM 8-K

__________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 9, 2021

__________________________________________________

ABCELLERA BIOLOGICS INC.

(Exact name of registrant as specified in its charter)

__________________________________________________

British Columbia	001-39781	Not Applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

2215 Yukon Street Vancouver, BC	V5Y 0A1
(Address of registrant’s principal executive office)	(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common shares	ABCL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02    Results of Operations and Financial Condition

On November 9, 2021, AbCellera Biologics Inc., (the “Company”), issued a press release announcing its financial and operational results for the quarter ended September 30, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01    Regulation FD Disclosure

In connection with its earnings call on November 9, 2021, to discuss its results for the quarter ended September 30, 2021, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.

The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01    Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release issued by AbCellera Biologics Inc. on November 9, 2021.
99.2	Corporate presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 9, 2021	ABCELLERA BIOLOGICS INC.
	By:	/s/ Carl L. G. Hansen
		Carl L. G. Hansen, Ph.D.
		Chief Executive Officer and Director (Principal Executive Officer)

EX-99.1

Exhibit 99.1

NEWS RELEASE

AbCellera Reports Q3 2021 Business Results

11/09/2021

● Total revenue of $6 million, compared to $9 million in Q3 2020

● Nine program starts in the quarter bringing cumulative total to 69, up 35% from Q3 2020

● Net loss of ($0.08) per share (basic and diluted) compared to a net loss of ($0.02) per share (basic and diluted) in Q3 2020

VANCOUVER, British Columbia, November 9, 2021 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“We continue to execute on our long-term business strategy and have achieved another quarter of strong business development and growth in the key metric of program starts,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “Our focus remains on the following top priorities: execution of our partnership business, forward integration of the platform to support all antibody drug discovery activities for the submission of an Investigational New Drug application, and investments in data science to increase the speed and scalability of our tech stack.”

Q3 2021 Business Summary

● Earned $5.5 million in total revenue.

● Incurred net loss of $21.4 million, compared to a net loss of $2.7 million in Q3 2020.

● Added 17 programs under contract and two new partners, resulting in a cumulative total of 155 programs under contract with 35 different partners.

● Started discovery on nine programs, bringing the cumulative number of program starts to 69.

● Confirmed one new molecule advanced into the clinic, bringing the cumulative total to five.

1

● Acquired TetraGenetics to expand capabilities for high-value transmembrane protein targets.

Key Business Metrics

Metric	September 30, 2020		September 30, 2021		Change %
Number of discovery partners		26		35		35	%
Programs under contract, cumulative		94		155		65	%
Program starts, cumulative		51		69		35	%
Molecules in the clinic		1		5		400	%

AbCellera added 17 discovery programs in Q3 to reach a cumulative total of 155 discovery programs as of September 30, 2021 (up 65% from 94 on September 30, 2020), that are either completed, in progress, or under contract with 35 different partners (up from 26 on September 30, 2020). AbCellera started discovery on an additional nine programs in Q3 to reach a cumulative total of 69 program starts (up from 51 on September 30, 2020). AbCellera’s partners advanced one additional molecule into the clinic in Q3 2021, bringing the cumulative total to five.

Discussion of Q3 2021 Financial Results

(expressed in thousands)	Three months ended September 30,				Nine months ended September 30,
	2020		2021		2020		2021
Revenue:
Research fees	$	4,362	$	5,128	$	17,247	$	14,330
Licensing revenue		-		190		-		20,692
Milestone payments		5,000		-		8,000		8,000
Royalty revenue		-		190		-		192,850
Total revenue	$	9,362	$	5,508	$	25,247	$	235,872

● Revenue – Total revenue was$5.5 million, compared to $9.4 million in Q3 2020, which is attributable to the reduction of milestone payments associated with COVID-19 treatments. Royalties associated with bamlanivimab were $0.2 million due to a temporary pause in usage until September 2, 2021 by the Assistant Secretary for Preparedness and Response and the Food and Drug Administration. Shipments from existing U.S. supply then resumed on a weekly basis, and subsequent to the end of the quarter, Eli Lilly reported that the U.S. government has ordered 614,000 additional doses of bamlanivimab with etesevimab to be delivered by January 31, 2022. The partnership business produced research fees of $5.1 million, compared to $4.4 million in Q3 2020. Licensing revenue was $0.2 million.

● Research & Development (R&D) Expenses – R&D expenses were $17.5 million, compared to $7.5 million in Q3 2020, reflecting continuing investments in the capacity and capabilities of AbCellera’s discovery and development platform.

● Sales & Marketing (S&M) Expenses – S&M expenses were $1.2 million, compared to $0.6 million in Q3 2020.

2

● General & Administrative (G&A) Expenses – G&A expenses were $11.3 million, compared to $3.0 million in Q3 2020, with the increase driven primarily by investments to support the growth of the company, non-cash stock-based compensation in line with publicly listed companies, and protecting intellectual property.

● Net Loss – Net loss was $21.4 million, or ($0.08) per share on both a basic and diluted basis compared to a net loss of $2.7 million, or ($0.02) per share on a basic and diluted basis, in Q3 2020.

● Liquidity – $753.5 million of cash, cash equivalents, and marketable securities and $43.6 million in accounts and accrued receivable.

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Standard Time (5:00 p.m. Eastern Standard Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Definition of Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. For example, as our business matures and to the extent programs are discontinued, we anticipate updating these metrics to reflect such changes.

Number of discovery partnersrepresents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our technology stack and our current level of market penetration. The metric also relates to our opportunities to secure programs under contract.

Programs under contractrepresent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover antibodies against one selected target. A target is any relevant antigen for which a partner

3

seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from technology access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties.

Program starts represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting near-term potential to earn research fees. Cumulatively, program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term.

Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

AbCellera Forward-looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking

4

statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Source: AbCellera Biologics Inc.

Inquiries

Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236) 521-6774

Business Development: Neil Berkley;bd@abcellera.com, +1(604) 559-9005

Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778) 729-9116

5

AbCellera Biologics Inc.

Condensed Consolidated Statements of Income (Loss) and

Comprehensive Income (Loss)

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data)

(Unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2020			2021			2020			2021
Revenue:
Research fees	$	4,362		$	5,128		$	17,247		$	14,330
Licensing revenue		-			190			-			20,692
Milestone payments		5,000			-			8,000			8,000
Royalty revenue		-			190			-			192,850
Total revenue		9,362			5,508			25,247			235,872
Operating expenses:
Royalty fees		-			-			-			23,622
Research and development(1)		7,495			17,450			20,757			44,853
Sales and marketing(1)		626			1,217			1,610			5,086
General and administrative(1)		2,968			11,271			6,116			28,958
Depreciation and amortization		41			3,666			1,508			10,493
Total operating expenses		11,130			33,604			29,991			113,012
Income (loss) from operations		(1,768	)		(28,096	)		(4,744	)		122,860
Other (income) expense
Other (income) expense		2,262			1,256			3,556			595
Grants and incentives		(1,337	)		(4,380	)		(10,217	)		(12,174	)
Total other (income) expense		925			(3,124	)		(6,661	)		(11,579	)
Net earnings (loss) before income tax		(2,693	)		(24,972	)		1,917			134,439
Income tax (recovery)		-			(3,592	)		-			40,923
Net earnings (loss)	$	(2,693	)	$	(21,380	)	$	1,917		$	93,516
Foreign currency translation adjustment		-			(1,508	)		-			644
Comprehensive income (loss)	$	(2,693	)	$	(22,888	)	$	1,917		$	94,160
Net earnings (loss) per share attributable to common shareholders
Basic	$	(0.02	)	$	(0.08	)	$	0.01		$	0.34
Diluted	$	(0.02	)	$	(0.08	)	$	0.01		$	0.29
Weighted-average common shares outstanding
Basic		153,049,739			278,933,760			152,413,300			273,642,542
Diluted		153,049,739			278,933,760			237,723,530			323,323,053

​​1 Exclusive of depreciation and amortization

6

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheet

(All figures in U.S. dollars. Amounts are expressed in thousands except share data)

(Unaudited)

	December 31, 2020		September 30, 2021
Assets
Current assets:
Cash and cash equivalents	$	594,116	$	517,694
Marketable securities		-		235,785
Total cash, cash equivalents, and marketable securities		594,116		753,479
Accounts and accrued receivable		213,239		43,633
Other current assets		5,970		6,635
Total current assets		813,325		803,747
Long term assets:
Property and equipment, net		17,923		91,584
Intangible assets		115,153		148,821
Goodwill		31,500		49,457
Investments in and loans to equity accounted investees		19,247		47,507
Other long-term assets		8,388		31,616
Total long-term assets		192,211		368,985
Total assets	$	1,005,536	$	1,172,732
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other liabilities	$	20,195	$	24,072
Current portion of contingent consideration payable		13,411		12,122
Income taxes payable		36,152		6,590
Accrued royalties payable		27,143		595
Deferred revenue		6,589		6,170
Total current liabilities		103,490		49,549
Long-term liabilities:
Operating lease liability		3,715		27,264
Deferred revenue and grant funding		25,894		59,682
Contingent consideration payable		9,148		44,948
Deferred tax liability		26,161		36,197
Other long-term liabilities		6,620		1,695
Total long-term liabilities		71,538		169,786
Total liabilities		175,028		219,335
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at    December 31, 2020 and September 30, 2021:  269,497,768 and    281,151,877 shares issued and outstanding at December 31,    2020 and September 30, 2021 respectively		710,387		718,088
Additional paid-in capital		5,919		26,945
Accumulated other comprehensive income		-		644
Accumulated earnings		114,202		207,720
Total shareholders' equity		830,508		953,397
Total liabilities and shareholders' equity	$	1,005,536	$	1,172,732

7

AbCellera Biologics Inc.

Condensed Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. dollars)

(Unaudited)

	Nine months ended September 30,
	2020			2021
Cash flows from operating activities:
Net income	$	1,917		$	93,516
Cash flows from operating activities:
Depreciation of property and equipment		1,507			3,060
Amortization of intangible assets		821			7,432
Amortization of operating lease right-of-use assets		335			1,895
Stock-based compensation		3,775			21,608
Deferred tax expense		-			(3,267	)
Other		440			888
Changes in operating assets and liabilities:
Accounts and accrued research fees receivable		(16,992	)		(34,329	)
Accrued royalties receivable		-			194,327
Income taxes payable		-			(29,563	)
Accounts payable and accrued liabilities		2,890			(313	)
Deferred revenue		22,431			9,051
Accrued royalties payable		-			(26,548	)
Operating lease liabilities		594			(327	)
Deferred grant income		4,592			27,324
Other assets		(898	)		(3,458	)
Net cash provided by operating activities		21,412			261,296
Cash flows from investing activities:
Purchases of property and equipment		(8,171	)		(49,022	)
Purchase of intangible assets		(5,000	)		-
Repayment of loan to related parties		1,573			-
Purchase of marketable securities		-			(245,314	)
Proceeds from marketable securities		-			9,527
Receipt of grant funding		-			9,807
Acquisitions		-			(11,457	)
Long-term investments and deposits		-			(17,534	)
Investment in and loans to equity accounted investees		-			(27,105	)
Net cash used in investing activities		(11,598	)		(331,098	)
Cash flows from financing activities:
Repayment of long-term debt		(16,971	)		(1,823	)
Payment of contingent consideration		-			(2,550	)
Proceeds from long-term debt		15,516			872
Payment of liability for in-licensing agreement		-			(5,000	)
Short-term borrowings		(387	)		-
Issuance of common shares pursuant to exercise of stock options		893			2,781
Proceeds from issuance of preferred shares - series A2 financing		74,663			-
Net cash provided by (used in) financing activities		73,714			(5,720	)
Effect of exchange rate changes on cash and cash equivalents		-			(900	)
Increase (decrease) in cash and cash equivalents		83,528			(76,422	)
Cash and cash equivalents, beginning of period		7,553			594,116
Cash and cash equivalents, end of period	$	91,081		$	517,694
Supplemental disclosure of non-cash investing and financing activities
Right-of-use assets obtained in exchange for operating lease obligation		567			26,976
Purchase of intangible assets in exchange for in-licensing agreement payable		9,060			-

8

EX-99.2

Q3 2021 Business Update NOV 9, 2021

DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Q3 2021 Business Update

155 9 Q3 2021. BUSINESS UPDATE SUMMARY. STRONG GROWTH OF CORE BUSINESS $754M 17 1 $44M NEW programs under contract NEW programs started MOLECULE entered clinical testing cumulative programs under contract in accounts & accrued receivable in cash, cash equivalents & marketable securities

OUR VISION. DOZENS OF IND FILINGS IN HALF THE TIME 100+ DISCOVERY PROGRAMS annually Tech Stack Preclinical Antibody Discovery Expansion into GMP / CMC Manufacturing Phase 1, 2, 3, Approval

155 Programs under contract royalties & milestones option to Invest equity / equity-like 5 131 with downstream participation neurodegeneration pain allergic inflammation ophthalmology infectious disease women’s health cardiovascular autoimmune diseases INDICATIONS INCLUDE DEAL STRUCTURES oncology Q3 2021 Business Update

UNLOCKING INNOVATION Next-Gen Modalities IgGs, IgMs, IgAs bispecific antibodies single domain CAR-T Cell therapies radioisotope conjugates CNS-delivered antibodies FOR DRUG DEVELOPERS OF ALL SIZES 6 Q3 2021 Business Update

6 targets multi-year 2 new partnerships that open new markets & pioneer new modalities oncology + multiple indications 10 targets multi-year 7 multiple indications Q3 2021 Business Update

Expand capabilities against difficult-to-drug targets with Acquisition of tetragenetics GPCR and ion channel proteins are high value, difficult-to-drug targets. Integrating TetraGenetics into our tech stack provides an optimized source of proteins for our antibody discovery efforts and solves a key challenge in pursuing these highly sought-after, but difficult-to-drug targets. 8 Q3 2021 Business Update

Creating value with bispecifics OrthoMab™ bispecific engineering platform, coupled with our discovery engine, provides partners with a rapid and complete solution for generating tailored, stable, and developable bispecific antibodies. 9 Q3 2021 Business Update

Empower next-gen anti-CD3 antibodies for oncology Large and growing market opportunity in the use of bispecifics specifically for T cell redirection in oncology through CD3 receptor engagement on T cells. 10 CD3+ T Cell Target Cell Q3 2021 Business Update

CONGRATULATIONS TO INVETX FOR ADVANCING IVX-01 into clinical testing IVX-01 is an antibody treatment for an undisclosed chronic indication in dogs. 11 Q3 2021 Business Update

Expand capabilities. build capacity. extend commercial reach. 12 Q3 2021 Business Update

Q3 2021 Financials update

Partnership business on track for strongest year on all key metrics. 14 FINANCIALS Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results. Discovery Partners Programs Under Contract Program Starts # of Cumulative # of Cumulative # of 0 20 10 35 15 5 30 25 2016 27 2020 2015 2017 2018 2019 Q3 2021 35 0 160 100 20 40 60 120 140 80 Q3 2021 103 2015 2018 2016 2017 2019 2020 155 70 0 10 50 20 40 60 30 2019 69 52 2015 2016 2018 Q3 2021 2017 2020 Q3 2021 Business Update

Five molecules in the clinic, over a dozen in preclinical development. 15 FINANCIALS Q3 2021 Business Update

$5.5M revenue reflects robust discovery partnership activity. 16 FINANCIALS Revenue USD Q3 2021 $5.1M Q3 2020 $5.5M $0.2M $4.4M $9.4M $0.2M $5.0M Q3 2021 Business Update

Operating expenses continue to reflect strengthening of the platform. 17 FINANCIALS RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN $7.5M Q3 2021 Q3 2020 $17.5M +$10.0M Operating Expenses USD $0.6M Q3 2020 Q3 2021 $1.2M +$0.6M Q3 2020 Q3 2021 $3.0M $11.3M +$8.3M Q3 2021 Business Update

NET EARNINGS (LOSS) 18 FINANCIALS Net loss of $21.4M: Equivalent to ($0.08) per share (basic & diluted). EARNINGS (LOSS) PER SHARE: BASIC & DILUTED Earnings / Loss USD -$21.4M $1.9M $93.5M 2021 2020 $0.34 DILUTED -$2.7M -$0.08 -$0.02 $0.01 $0.29 Q3 First 9 Months Q3 First 9 Months 2021 2020 2021 2020 2021 2020 Q3 2021 Business Update BASIC

Total short-term liquidity nearly $800 million. 19 FINANCIALS Cash Flows USD ($0.9M) $261.3M $49.0M PP&E ($5.7M) ($95.3M) $594.1M $753.5M Additionally, $44M AR + accrued AR balance at quarter end 1. excluding marketable securities Q3 2021 Business Update

20 Thank You Q3 2021 Business Update

XML

Document and Entity Information	Nov. 09, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 09, 2021
Entity Registrant Name	ABCELLERA BIOLOGICS INC.
Entity Central Index Key	0001703057
Entity Incorporation, State or Country Code	A1
Entity File Number	001-39781
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	2215 Yukon Street
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V5Y 0A1
City Area Code	604
Local Phone Number	559-9005
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common shares
Trading Symbol	ABCL
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false